CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $520,038, lower than 95% of all stocks globally
- PositionOperating margin is -56078.1%, lower than 95% of its Biotechnology peers (median -34.2%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.48BHKD443.17M · vs all stocks (USD)
Revenue (TTM)
4.08MCNY520.04K · vs all stocks (USD)
Beta
2.57xvs all stocks
52-Week Change
179.22%vs all stocks
Market Capitalization
3.48BHKD443.17M · vs all stocks (USD)
Enterprise Value
3.18BHKD405.47M · vs all stocks (USD)
Forward P/E
2.05xvs Biotechnology peers
Enterprise to Revenue
779.70xvs Biotechnology peers
Enterprise to EBITDA
-11.49xvs Biotechnology peers
Return on Assets (TTM)
-25.07%vs Biotechnology peers
Revenue (TTM)
4.08MCNY520.04K · vs all stocks (USD)
Revenue per Share (TTM)
0.0030CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-99.50%vs Biotechnology peers
Gross Profit (TTM)
3.85MCNY490.36K · vs all stocks (USD)
EBITDA (TTM)
-276.77MCNY-35.29M · vs all stocks (USD)
Net Income (TTM)
-238.68MCNY-30.43M · vs all stocks (USD)
Operating Cash Flow (TTM)
-226.73MCNY-28.91M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-14.88MCNY-1.90M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.50MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
765.00KCNYFY2025 · Dec 31, 2025Gross Profit
2.74MCNYFY2025 · Dec 31, 2025Operating Income
-217.07MCNY-32.19M · vs all stocks (USD)
Pre-tax Income
-205.09MCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
-205.09MCNYFY2025 · Dec 31, 2025EBIT
-204.72MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-174.32MCNYFY2025 · Dec 31, 2025Research & Development
182.34MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
33.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.33MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
377.00KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1600CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.26BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.26BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-205.09MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-175.63MCNYFY2025 · Dec 31, 2025Free Cash Flow
-175.64MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
267.63MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-205.09MCNYFY2025 · Dec 31, 2025Stock-based Compensation
6.69MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-5.95MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
40.99MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.27MCNYFY2025 · Dec 31, 2025Capital Expenditures
-12.00KCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00CNYFY2025 · Dec 31, 2025Sale of Investments
0.00CNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-12.00KCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-93.99MCNYFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-73.99MCNYFY2025 · Dec 31, 2025Other Financing Charges
143.77MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-23.72MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.30BSharesUpdated Aug 19, 2026Float Shares
795.91MSharesUpdated Aug 19, 2026% Held by Insiders
34.14%vs all stocks
% Held by Institutions
14.48%vs all stocks
Total Cash (MRQ)
328.48MCNY41.88M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2170CNYUpdated Aug 19, 2026Total Debt (MRQ)
12.35MCNY1.57M · vs all stocks (USD)
Current Ratio (MRQ)
0.1920xvs Biotechnology peers
Book Value per Share (MRQ)
-1.61CNYUpdated Aug 19, 2026Total Assets
457.92MCNY67.91M · vs all stocks (USD)
Total Current Assets
335.83MCNYFY2025 · Dec 31, 2025Total Liabilities
2.26BCNYFY2025 · Dec 31, 2025Total Non-current Assets
122.09MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
504.60MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.75BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
267.63MCNYFY2025 · Dec 31, 2025Other Short-term Investments
18.39MCNYFY2025 · Dec 31, 2025Accounts Receivable
3.00KCNYFY2025 · Dec 31, 2025Inventory
9.86MCNYFY2025 · Dec 31, 2025Accounts Payable
107.99MCNYFY2025 · Dec 31, 2025Short-term Debt
10.61MCNYFY2025 · Dec 31, 2025Long-term Debt
0.00CNYFY2025 · Dec 31, 2025Common Stock (Book)
839.00KCNYFY2025 · Dec 31, 2025Retained Earnings
-10.75BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
-1.80BCNY-266.54M · vs all stocks (USD)
Treasury Stock
23.00KCNYFY2025 · Dec 31, 202552-Week Low
0.6700HKDUpdated Aug 19, 202652-Week High
3.20HKDUpdated Aug 19, 202652-Week Change
179.22%vs all stocks
Beta
2.57xvs all stocks
50-Day MA
1.78HKDUpdated Aug 19, 2026200-Day MA
2.31HKDUpdated Aug 19, 2026Avg 10-Day Volume
6.91MSharesUpdated Aug 19, 2026Avg 30-Day Volume
5.34MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.1900CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -56078.1%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -560.781Industry median: -0.34Industry P5: -43.55Peers compared: 261
Current ratio is 0.19×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.19Industry median: 5.64Industry P5: 1.06Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $520,038, lower than 95% of all stocks globallySignificant
Revenue (USD): 520,037.83Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Delcath Systems Inc.
Tier 1ProductionApproval-Gated PipelineRule
Baotou Dongbao Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Varex Imaging Corporation
Tier 1ProductionApproval-Gated PipelineRule
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jw Pharmaceutical Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangxi Synergy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hubei Goto Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Haisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pacific Biosciences of California, Inc.
Tier 1ProductionApproval-Gated PipelineRule